These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10699326)

  • 21. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo.
    Sin JI; Kim J; Pachuk C; Weiner DB
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):751-8. PubMed ID: 10973449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes.
    Sin JI; Kim JJ; Ugen KE; Ciccarelli RB; Higgins TJ; Weiner DB
    Eur J Immunol; 1998 Nov; 28(11):3530-40. PubMed ID: 9842896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with HSV-2 gB-CCL19 Fusion Constructs Protects Mice against Lethal Vaginal Challenge.
    Yan Y; Hu K; Deng X; Guan X; Luo S; Tong L; Du T; Fu M; Zhang M; Liu Y; Hu Q
    J Immunol; 2015 Jul; 195(1):329-38. PubMed ID: 25994965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
    Tengvall S; O'Hagan D; Harandi AM
    Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.
    Cortesi R; Ravani L; Rinaldi F; Marconi P; Drechsler M; Manservigi M; Argnani R; Menegatti E; Esposito E; Manservigi R
    Int J Pharm; 2013 Jan; 440(2):229-37. PubMed ID: 22743007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant.
    Zhu M; Xu X; Liu H; Liu X; Wang S; Dong F; Yang B; Song G
    J Med Microbiol; 2003 Mar; 52(Pt 3):223-228. PubMed ID: 12621087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
    Gyotoku T; Ono F; Aurelian L
    Vaccine; 2002 Jun; 20(21-22):2796-807. PubMed ID: 12034107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moderate exercise is associated with enhanced antigen-specific cytokine, but not IgM antibody production in aged mice.
    Kohut ML; Boehm GW; Moynihan JA
    Mech Ageing Dev; 2001 Aug; 122(11):1135-50. PubMed ID: 11389929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model.
    Sin JI; Bagarazzi M; Pachuk C; Weiner DB
    DNA Cell Biol; 1999 Oct; 18(10):771-9. PubMed ID: 10541436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
    Morrison LA; Zhu L; Thebeau LG
    J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.
    Sin JI; Kim JJ; Arnold RL; Shroff KE; McCallus D; Pachuk C; McElhiney SP; Wolf MW; Pompa-de Bruin SJ; Higgins TJ; Ciccarelli RB; Weiner DB
    J Immunol; 1999 Mar; 162(5):2912-21. PubMed ID: 10072541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A vaccinia virus--herpes simplex virus (HSV) glycoprotein B1 recombinant or an HSV vaccine overcome the HSV type 2 induced humoral immunosuppression and protect against vaginal challenge in BALB/c mice.
    Fleck M; Podlech J; Weise K; Falke D
    Med Microbiol Immunol; 1994 May; 183(2):87-94. PubMed ID: 7935163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
    Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
    J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-immunization with plasmids coding the full length and a soluble form of glycoprotein D of HSV-2 induces protective cellular and humoral immune response in mice.
    Fló J
    Vaccine; 2003 Mar; 21(11-12):1239-45. PubMed ID: 12559804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4+ CTL responses.
    Cooper D; Pride MW; Guo M; Cutler M; Mester JC; Nasar F; She J; Souza V; York L; Mishkin E; Eldridge J; Natuk RJ
    Vaccine; 2004 Nov; 23(2):236-46. PubMed ID: 15531043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2.
    Milligan GN; Bernstein DI
    Virology; 1995 Oct; 212(2):481-9. PubMed ID: 7571418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.
    Flechtner JB; Long D; Larson S; Clemens V; Baccari A; Kien L; Chan J; Skoberne M; Brudner M; Hetherington S
    Vaccine; 2016 Oct; 34(44):5314-5320. PubMed ID: 27642130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.